{"url_path":"/sec/inm/8-k/2026-04-27/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1728328/0001213900-26-048064-index.html","accession_number":"0001213900-26-048064","cik":"0001728328","ticker":"INM","issuer_name":"InMed Pharmaceuticals Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1728328/0001213900-26-048064-index.html","primary_entity_key":"0001728328","primary_entity_name":"InMed Pharmaceuticals Inc."},"word_count":74,"has_tables":true,"body_markdown":"**Item 8.01 Other Events.**\n\n \n\nOn April 27, 2026, the Company issued a press\nrelease announcing the amendments to the Sabby Preferred Investment Options and the Wainwright Preferred Investment Options. A copy of\nthe press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The press release contains forward-looking\nstatements and includes cautionary statements identifying important factors that could cause actual results to differ materially from\nthose in the forward-looking statements."}